Growth increments with low dose intermittent growth hormone and fluoxymesterone in first year of therapy in hypopituitarism.
Pediatrics, 1979/3;63(3):386-8.
PMID: 220585
Impact factor: 9.703
Abstract
The availability of a commercial preparation of human growth hormone (hGH) prompted a study in children with hypopituitarism to determine the efficacy of a lower dose of hGH. Thirteen children, ages 4 years 3 months to 13 years 7 months, were given hGH concomitant with fluoxymesterone in an intermittent regimen. The hGH was given intramuscularly, 1 IU daily for 12 to 36 days in each course. There were four courses per year. The fluoxymesterone was given orally, 1 to 2 mg. The total amount of hGH administered was between 48 and 112 IU per year, as compared with the regimen of 312 IU per year, 2 units three times a week. The growth velocity in all 13 children improved, and the mean growth velocity was 6.4 cm +/- 1.13 SD. The mean bone age increment was 0.57 years +/- 0.14 SEM in one chronological year of therapy. The low dose regimen permits a significant reduction in cost of hGH without causing undue advance in bone age.
MeSH terms
Adolescent; Age Determination by Skeleton; Body Height; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Fluoxymesterone; Growth Hormone; Humans; Hypopituitarism; Male
More resources
EndNote: Download